TORONTO, Aug. 28,
2024 /CNW/ - HLS Therapeutics Inc. ("HLS" or the
"Company") (TSX: HLS), a pharmaceutical company focusing on
addressing unmet needs in the treatment of psychiatric disorders
and cardiovascular disease, announces that Craig Millian, Chief Executive Officer, will
present at H.C. Wainwright's 26th Annual Global Investment
Conference, which takes place September
9-11, 2024 at the Lotte New York Palace Hotel in
New York City.
HLS will present on September 11,
2024, at 12:30 p.m. Eastern
Time. The Company's presentation will be webcast at:
https://journey.ct.events/view/33b42a87-defc-4512-b0e4-fdcfde358d00.
The presentation will be archived for 90 days and will also be
available on the Events page in the Investor section of HLS's
website.
Mr. Millian will also host one-on-one meetings with investors at
the conference. To request a one-on-one meeting, please contact
your H.C. Wainwright representative. For more information about the
conference, please visit the conference website.
ABOUT HLS THERAPEUTICS INC.
Formed in 2015, HLS is a
pharmaceutical company focused on the acquisition and
commercialization of late-stage development, commercial stage
promoted and established branded pharmaceutical products in the
North American markets. HLS's focus is on products targeting the
central nervous system and cardiovascular therapeutic areas. HLS's
management team is composed of seasoned pharmaceutical executives
with a strong track record of success in these therapeutic areas
and at managing products in each of these lifecycle stages. For
more information visit: www.hlstherapeutics.com
SOURCE HLS Therapeutics Inc.